| Source: |
| Type: |
| “NKG2D” itself is a receptor on immune cells, and most research focuses on its ligands—such as MICA, MICB, and the UL16-binding proteins (ULBPs)—that are expressed by tumor cells or within the tumor microenvironment. MICA and MICB • Expression: – Frequently overexpressed on the surface of transformed cells in cancers such as colorectal, ovarian, breast, and pancreatic cancers. • Prognosis: – In some studies, high levels of MICA/B on tumor cells have been correlated with enhanced NK cell-mediated lysis and better prognosis. 2. ULBPs (ULBP1, ULBP2, ULBP3, etc.) -Overexpression of certain ULBP family members has been associated with increased tumor recognition by NK and CD8⁺ T cells, potentially correlating with improved survival in some studies (e.g., ovarian cancer). – In contrast, increased soluble ULBP levels have been linked to immune evasion and worse outcomes in other contexts. |
| 3098- | RES, | Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers |
| - | Review, | Var, | NA |
| 1470- | SFN, | Rad, | Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Lung, | A549 | - | in-vitro, | lymphoma, | U937 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1104 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid